Get started
Keros Therapeutics, Inc.Keros Therapeutics, Inc.Keros Therapeutics, Inc.

Keros Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

KROS chart


Full chart

KROS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.72 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.21 USD
Net income (FY)
‪−152.99 M‬ USD
Revenue (FY)
‪151.00 K‬ USD
Shares float
‪29.84 M‬
Beta (1Y)
−0.70

Employees


Employees (FY)
136
Change (1Y)
+31 +29.52%
Revenue / Employee (1Y)
‪1.11 K‬ USD
Net income / Employee (1Y)
‪−1.12 M‬ USD

About Keros Therapeutics, Inc.


Sector
Health Technology
CEO
Jasbir S. Seehra
Headquarters
Lexington
Website
kerostx.com
Founded
2015
FIGI
BBG00H1HP9G9
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

KROS news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of KROS is 67.91 USD — it has decreased by −0.47% in the past 24 hours. Watch Keros Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Keros Therapeutics, Inc. stocks are traded under the ticker KROS.
KROS stock has risen by 14.28% compared to the previous week, the month change is a 12.04% rise, over the last year Keros Therapeutics, Inc. has showed a 116.69% increase.
We've gathered analysts' opinions on Keros Therapeutics, Inc. future price: according to them, KROS price has a max estimate of 107.00 USD and a min estimate of 76.00 USD. Watch KROS chart and read a more detailed Keros Therapeutics, Inc. stock forecast: see what analysts think of Keros Therapeutics, Inc. and suggest that you do with its stocks.
KROS reached its all-time high on Dec 8, 2020 with the price of 88.80 USD, and its all-time low was 19.10 USD and was reached on Apr 8, 2020. View more price dynamics on KROS chart.
See other stocks reaching their highest and lowest prices.
KROS stock is 4.38% volatile and has beta coefficient of −0.70. Track Keros Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Keros Therapeutics, Inc. there?
Today Keros Therapeutics, Inc. has the market capitalization of ‪2.52 B‬, it has increased by 0.13% over the last week.
Yes, you can track Keros Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Keros Therapeutics, Inc. is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
KROS earnings for the last quarter are −1.41 USD per share, whereas the estimation was −1.28 USD resulting in a −10.27% surprise. The estimated earnings for the next quarter are −1.37 USD per share. See more details about Keros Therapeutics, Inc. earnings.
Keros Therapeutics, Inc. revenue for the last quarter amounts to ‪388.00 K‬ USD, despite the estimated figure of 0.00 USD. In the next quarter, revenue is expected to reach ‪46.15 K‬ USD.
KROS net income for the last quarter is ‪−52.96 M‬ USD, while the quarter before that showed ‪−45.26 M‬ USD of net income which accounts for −17.01% change. Track more Keros Therapeutics, Inc. financial stats to get the full picture.
No, KROS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2024, the company has 136.00 employees. See our rating of the largest employees — is Keros Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Keros Therapeutics, Inc. EBITDA is ‪−202.89 M‬ USD, and current EBITDA margin is ‪−112.00 K‬%. See more stats in Keros Therapeutics, Inc. financial statements.
Like other stocks, KROS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Keros Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Keros Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Keros Therapeutics, Inc. stock shows the buy signal. See more of Keros Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.